Corvus Pharmaceuticals (CRVS) Stock Statistics & Valuation Metrics

Corvus Pharmaceuticals has a market cap or net worth of $1.23B. The enterprise value is $1.23B.

Corvus Pharmaceuticals has 83,992,410 shares outstanding. The number of shares has decreased by -2.65% in one year.

Corvus Pharmaceuticals’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -69.15%.

The current PE Ratio of Corvus Pharmaceuticals is ―. Corvus Pharmaceuticals’s PEG ratio is 0.49.

In the last 12 months, Corvus Pharmaceuticals had revenue of 0.00 and earned -15.28M in profits. Earnings per share was -0.19.

In the last 12 months, operating cash flow was -32.80M and capital expenditures -174.00K, giving a free cash flow of -32.97M billion.

Corvus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Corvus Pharmaceuticals upcoming earnings date is May 11, 2026, TBA (Confirmed).

Corvus Pharmaceuticals as a current ratio of 6.21, with Debt / Equity ratio of 1.53%

In the past 12 months, Corvus Pharmaceuticals has paid 0.00 in taxes.

Corvus Pharmaceuticals EV to EBITDA ratio is -14.07, with an EV/FCF ratio of -18.33.

Corvus Pharmaceuticals has $56.75M in cash and marketable securities with $937.00K in debt, giving a net cash position of $55.81M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Corvus Pharmaceuticals is $32.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy